
The zzso delivery of systemic chemotherapy given with zzso zzso is driven by an understanding of: the zzso of normal tissue response to zzso zzso zzso and by zzso advances in vascular access and in the availability of portable zzso zzso Since zzso variation exists in the zzso activity of zzso normal zzso like the gut and bone zzso a potential therapeutic gain can be realized by the zzso administration of zzso zzso agents at biological times when these normal zzso are in a different cell phase and thus relatively spared zzso The reasons for this are complex and possibly include newly described zzso genes that may influence the cell zzso Another important aspect of zzso is based on zzso behavior of zzso zzso radiation zzso agents, especially zzso zzso In this review laboratory and clinical evidence is presented for using zzso zzso or the zzso zzso zzso when best tolerated zzso Although the main body of this work has been accomplished with pure chemotherapy schedules, there is emerging clinical evidence this approach to treatment also applies to the application of zzso This knowledge has been exploited only recently in the zzso These data should be viewed as a call for additional studies to investigate the precise timing of systemic zzso radio zzso to zzso toxicity and maximize treatment effect, especially with newer and potentially more toxic zzso zzso 

